Non-achievement of clinical targets in patients with type 2 diabetes mellitus

Medical Journal of Malaysia

Volumn 59, Issue 2, 2004, Pages 177-184

  Eid, M ^a   Mafauzy, M ^a   Faridah, A R ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Body mass index; Dyslipidaemia; Hypertension; Type 2 diabetes

Indexed keywords

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE DISTRIBUTION; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALAYSIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; STATISTICAL MODEL;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LINEAR MODELS; MALAYSIA; MALE; OBESITY;

EID: 16644369986     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, & Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-146.
2. American Diabetes Association. Standards of Medical Care for Patients With Diabetes Mellitus (Position Statement). Diabetes Care 2002; 25 (1): 213-29.
3. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999 (more on cardiovascular disease). Diabetes Care 2000; 23 (6): 845-52.
4. American Diabetes Association. American Diabetes Association (1998). Diabetic retinopathy (position Statement). Diabetes Care 1998; 21 (Suppl. 1): S47-S49.
5. American Diabetes Association. Diabetic retinopathy (Position Statement). Clinical Diabetes 2001; 19 (1): 29-32.
6. American Diabetes Association. Diabetic retinopathy (Position Statement). Diabetes Care 2002; 25 (Suppl. 1): S90-S93.
7. American Diabetes Association. Diabetic nephropathy (position statement). Diabetes Care 1998; 21 (Suppl. 1): S50-S53.
8. American Diabetes Association. Diabetic nephropathy (Position Statement). Diabetes Care 2002; 25 (Suppl. 1): S85-S89.
9. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS33). Lancet 1998; 352: 837-53.
10. Bloomgarden ZT. The European Association for the Study of Diabetes Annual Meeting, 1998 (Complications of diabetes). Diabetes Care 1999; 22 (8): 1364-370.
11. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999 (nephropathy and neuropathy). Diabetes Care 2000; 23 (4): 549-56.
12. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes (Consensus Statement). Diabetes Care 1998; 21 (9): 1551-59.
13. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes (consensus statement). Diabetes Care 1989; 12 (8): 573-79.
14. American Diabetes Association. Treatment of hypertension in diabetes (consensus statement). Diabetes Care 1993; 16 (10): 1394-401.
15. American Diabetes Association. Treatment of hypertension in diabetes (consensus statement). Diabetes Care 1996; 19 (Suppl. 1): S107-S113.
16. American Diabetes Association. Treatment of hypertension in adults with diabetes (Position Statement). Diabetes Care 2002g; 25 (Suppl. 1):S71-S73.
17. American Diabetes Association. Treatment of hypertension in adults with diabetes (Position statement). Diabetes Care 2002; 25 (1): 199-201.
18. Arauz-Pacheco C, Parrott MA, & Raskin P. The treatment of hypertension in adult patients with diabetes (Technical Review). Diabetes Care 2002; 25 (1): 134-47.
19. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-13.
20. The National Cholesterol Education Program (NCEP)O. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-497.
21. Mohamad M, Arshad F, Mohd Noor MI, & Ali R. Prevalence of dyslipidaemia in non-insulin-dependent diabetic patients attending armed forces clinics in Kuala Lumpur. Asia Pacific J Clin Nutr 1997; 6 (3): 203-206.
22. Valle T, Koivisto VA, Reunanen A, Kangas T, & Rissanen, A. Glycemic control in patients with diabetes in Finland. Diabetes Care 1999; 22 (4): 575-79.
23. Miller CD, Phillips LS, Tate MK, Porwoll JM, Rossman SD, Cronmiller N, & Gebhart SSP. Meeting American Diabetes Association Guidelines in Endocrinologist Practice. Diabetes Care 2000; 23 (4): 444-48.
24. Paterson JR, Pettigrew AR, Dominiczak MH, & Small M. Screening for hyperlipidaemia in diabetes mellitus. Relation to glycaemic control. Ann Clin Biochem 1991; 28: 354-58.
25. Mafauzy M, Mokhtar N, Wan Muhamad WB, & Musalmah M. Diabetes mellitus and associated cardiovascular risk factors in North-East Malaysia. Asian-Pacific J Public Health 1999; 11 (1): 16-19.
26. Kanters SDJM, Algra A, Bruint TWA, Erkelens DW, & Banga JD. Intensive lipid-lowering strategy in patients with diabetes milletus. Diabetic Medicine 1999; 16: 500-508.
27. Mustaffa BE, Wan Mohamad WB, Chan SP, Rokiah P, Mafauzy M, Kumari S, Chandran AA, Ong GKC, Jorgensen LN & Yeo JP. The current status of diabetes management in Malaysia. J ASEAN Fed Endo Soc 1998; 16(2): 1-13.